Assessing anticancer drug utilization patterns through WHO prescribing indicators at a specialized cancer hospital in Peshawar

M. Saquib Hasnain, Safa Bakhtawar, Marina Khan, Sohail Ahmad, Mohsin Raziq, Muhammad Ashfaq, Md. Asaduzzaman Khan, Syed Abdullah Shah, Syed Muhammad Ashhad Halimi, Imran FarooqInternational Journal of Basic & Clinical Pharmacology 2025 · DOI

Abstract

Background: Efficient utilization of anticancer agents is crucial for effective malignancy treatment and cost management. WHO Prescribing Indicators provide a standardized measure for assessing drug usage. This study aimed to evaluate anticancer drug utilization patterns in a specialized oncology hospital using these indicators. Methods: A cross-sectional analysis involved reviewing medical records of anticancer drug prescriptions at a designated cancer treatment facility. Key WHO prescribing indicators, including drug per prescription average, proportions of anticancer drugs and generics usage, were assessed. Results: Analysis of 900 prescriptions revealed an average of 8.36 drugs per prescription, with 2.27 being anticancer drugs and 4.93 adjuvants. Notably, 71% of medications were prescribed generically and 85% were on the Essential Medicines List. Conclusions: This study highlights the value of WHO Prescribing Indicators in analysing anticancer drug utilization trends. Addressing prescribing deficiencies can refine treatment protocols, promote judicious pharmaceutical use and elevate patient care standards.

Introduction

Cancer treatment is notoriously complex and expensive, often requiring a "cocktail" of cytotoxic agents and supportive (adjuvant) drugs. In developing nations, "irrational" drug use—such as over-prescribing, using expensive brand names over generics, or ignoring standardized essential medicine lists—can lead to financial catastrophe for patients and increased risks of adverse drug reactions.

The authors address the lack of standardized data regarding how anticancer drugs are actually utilized in specialized clinical settings in Pakistan. By using the World Health Organization (WHO) prescribing indicators, they provide a measurable baseline to evaluate the rationality, safety, and cost-effectiveness of current oncological pharmacotherapy.

Methods

The researchers conducted a cross-sectional analysis of medical records at a specialized cancer facility in Peshawar.

  • Sample Size: 900 prescriptions collected between January 2023 and December 2023, totaling 7,530 individual drug entries.
  • Inclusion/Exclusion: The study included patients receiving anticancer therapy in day-care units and wards. It excluded pregnant patients, those receiving only supportive care, and those receiving only radiotherapy.
  • Metrics: The study utilized WHO core prescribing indicators, including the average number of drugs per encounter, percentage of drugs prescribed by generic name, and percentage of drugs prescribed from the Essential Medicines List (EML).

Results

Disease Distribution and Demographics

The study found a notable female predominance (59% vs. 41% male), largely driven by the high prevalence of breast cancer, which accounted for 31.33% of all cases. The most affected age group was 51–60 years (24.8%). In terms of cancer categories, Carcinoma was the most prevalent (80.88%), followed by Sarcoma (7%) and Lymphoma (6.33%).

Distribution of major cancer categories identified in the study, highlighting the dominance of carcinoma.

Prescribing Patterns and WHO Indicators

The analysis revealed a significant burden of polypharmacy, with an average of 8.36 drugs per prescription. This included an average of 2.27 anticancer drugs and 4.93 adjuvant drugs (such as anti-emetics and analgesics).

Regarding drug selection and naming, 85% of the prescribed drugs were on the Essential Medicines List. However, only 71% of medications were prescribed by their generic names. Additionally, 86% of the total drugs prescribed were injectables, reflecting the intensive clinical infrastructure required for chemotherapy.

Summary of key WHO prescribing indicators, including drug averages per prescription and adherence to generic naming and EML.

Discussion and Conclusion

The high average of 8.36 drugs per prescription suggests a significant risk for drug-drug interactions and patient non-adherence due to regimen complexity. While EML adherence (85%) is relatively high, it falls short of the near-perfect adherence seen in similar studies in other regions. The gap in generic prescribing (71%) represents a critical opportunity to reduce the economic burden on patients.

In conclusion, this study highlights the value of WHO Prescribing Indicators in analyzing anticancer drug utilization trends. Addressing prescribing deficiencies—specifically by promoting generic drugs and managing polypharmacy—can refine treatment protocols and elevate patient care standards in specialized oncology settings.

Summary updated

Abstract

Background: Efficient utilization of anticancer agents is crucial for effective malignancy treatment and cost management. WHO Prescribing Indicators provide a standardized measure for assessing drug usage. This study aimed to evaluate anticancer drug utilization patterns in a specialized oncology hospital using these indicators. Methods: A cross-sectional analysis involved reviewing medical records of anticancer drug prescriptions at a designated cancer treatment facility. Key WHO prescribing indicators, including drug per prescription average, proportions of anticancer drugs and generics usage, were assessed. Results: Analysis of 900 prescriptions revealed an average of 8.36 drugs per prescription, with 2.27 being anticancer drugs and 4.93 adjuvants. Notably, 71% of medications were prescribed generically 85% were on the Essential Medicines List. Opportunities for enhancing efficiency, like promoting generic drugs and reducing injectable anticancer agents, were identified. Conclusions: This study highlights the value of WHO Prescribing Indicators in analysing anticancer drug utilization trends. Addressing prescribing deficiencies can refine treatment protocols, promote judicious pharmaceutical use and elevate patient care standards. Future efforts should focus on targeted strategies to rectify these shortcomings, emphasizing ongoing research and quality improvement in oncologic pharmacotherapy.
BibTeX
@article{hasnain2025assessing,
  author = {M. Saquib Hasnain and Safa Bakhtawar and Marina Khan and Sohail Ahmad and Mohsin Raziq and Muhammad Ashfaq and Md. Asaduzzaman Khan and Syed Abdullah Shah and Syed Muhammad Ashhad Halimi and Imran Farooq},
  title = {{Assessing anticancer drug utilization patterns through WHO prescribing indicators at a specialized cancer hospital in Peshawar}},
  journal = {International Journal of Basic \& Clinical Pharmacology},
  year = {2025},
  doi = {10.18203/2319-2003.ijbcp20250475},
}
Figure